EP2057190A4 - Monoklonale anti-interferon-alpha-antikörper und verwendungsverfahren dafür - Google Patents

Monoklonale anti-interferon-alpha-antikörper und verwendungsverfahren dafür

Info

Publication number
EP2057190A4
EP2057190A4 EP07840833A EP07840833A EP2057190A4 EP 2057190 A4 EP2057190 A4 EP 2057190A4 EP 07840833 A EP07840833 A EP 07840833A EP 07840833 A EP07840833 A EP 07840833A EP 2057190 A4 EP2057190 A4 EP 2057190A4
Authority
EP
European Patent Office
Prior art keywords
methods
monoclonal antibodies
interferon alpha
alpha monoclonal
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07840833A
Other languages
English (en)
French (fr)
Other versions
EP2057190A2 (de
Inventor
Jacques Banchereau
Kiley Prilliman
Virginia Pascual
Anna Karolina Palucka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of EP2057190A2 publication Critical patent/EP2057190A2/de
Publication of EP2057190A4 publication Critical patent/EP2057190A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07840833A 2006-08-09 2007-08-09 Monoklonale anti-interferon-alpha-antikörper und verwendungsverfahren dafür Withdrawn EP2057190A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83659906P 2006-08-09 2006-08-09
PCT/US2007/075616 WO2008021976A2 (en) 2006-08-09 2007-08-09 Anti-interferon alpha monoclonal antibodies and methods for use

Publications (2)

Publication Number Publication Date
EP2057190A2 EP2057190A2 (de) 2009-05-13
EP2057190A4 true EP2057190A4 (de) 2010-07-28

Family

ID=39082973

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07840833A Withdrawn EP2057190A4 (de) 2006-08-09 2007-08-09 Monoklonale anti-interferon-alpha-antikörper und verwendungsverfahren dafür

Country Status (3)

Country Link
EP (1) EP2057190A4 (de)
JP (1) JP5230022B2 (de)
WO (1) WO2008021976A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5837730B2 (ja) 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
JP2010512315A (ja) * 2006-12-06 2010-04-22 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
EP2687232A1 (de) * 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
CN102083859B (zh) * 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN106589122B (zh) * 2015-10-20 2020-10-27 中国人民解放军军事医学科学院生物工程研究所 人源抗人多亚型干扰素α抗体及其应用
WO2019178601A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Peptide vaccines against interleukin-31
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
RU2737466C1 (ru) * 2019-12-30 2020-11-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гуманизированное нейтрализующее антитело к интерферону-бета человека
CN112129952B (zh) * 2020-09-21 2023-06-06 普健生物（武汉）科技有限公司 一种检测人可溶性cd14的化学发光试剂盒
CN116284368B (zh) * 2022-06-15 2025-05-09 重庆艾生斯生物工程有限公司 抗人MxA抗体或其抗原结合部分

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066649A2 (en) * 2001-02-22 2002-08-29 Genentech, Inc. ANTI-INTERFERON-α ANTIBODIES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066649A2 (en) * 2001-02-22 2002-08-29 Genentech, Inc. ANTI-INTERFERON-α ANTIBODIES

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANG K C ET AL: "MOLECULAR AND FUNCTIONAL ANALYSIS OF THE VIRUS- AND INTERFERON-INDUCIBLE HUMAN MXA PROMOTER", ARCHIVES OF VIROLOGY, NEW YORK, NY, US, vol. 117, 1991, pages 1 - 15, XP008007812, ISSN: 0304-8608 *
CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666 *
FRAY M D ET AL: "Validation of an Mx/CAT reporter gene assay for the quantification of bovine type-I interferon", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 249, no. 1-2, 1 March 2001 (2001-03-01), pages 235 - 244, XP004317487, ISSN: 0022-1759 *
LITTLE M ET AL: "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 364 - 370, XP004215163, ISSN: 0167-5699 *
OVERALL M L ET AL: "FUNCTIONAL ANALYSIS OF INTERFERON-ALPHA SUBTYPES USING MONOCLONAL ANTIBODIES TO INTERFERON-ALPHA4A-SUBTYPE REACTIVITY, NEUTRALISATION OF BIOLOGICAL ACTIVITIES AND EPITOPE ANALYSIS", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 29, no. 3, 1992, pages 391 - 399, XP009001288, ISSN: 0161-5890 *
RONNI T ET AL: "THE PROXIMAL INTERFERON-STIMULATED RESPONSE ELEMENTS ARE ESSENTIAL FOR INTERFERON RESPONSIVENESS: A PROMOTER ANALYSIS OF THE ANTIVIRAL MXA GENE", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 18, no. 9, September 1998 (1998-09-01), pages 773 - 781, XP008007716, ISSN: 1079-9907 *

Also Published As

Publication number Publication date
JP2010500380A (ja) 2010-01-07
JP5230022B2 (ja) 2013-07-10
WO2008021976A3 (en) 2008-11-13
EP2057190A2 (de) 2009-05-13
WO2008021976A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
EP2029173A4 (de) Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
EP2086583A4 (de) Vollständig humane anti-vegf-antikörper und verfahren zu ihrer verwendung
EP2104513A4 (de) Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
EP2212432A4 (de) Vollständig menschliche anti-vegf-antikörper und verwendungsverfahren
EP2373691A4 (de) Anti-fxi-antikörper und verfahren zu ihrer verwendung
EP2091975A4 (de) Antikörper gegen die egfr-familie, bispezifische antikörper gegen die egfr-familie und verfahren zu ihrer verwendung
EP2032159A4 (de) Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
FR20C1033I2 (fr) Anticorps anti-cd79b, immuno-conjugues et procedes d'utilisation
EP2057465A4 (de) Organspezifische proteine und anwendungsverfahren dafür
EP2350655A4 (de) Verfahren zur verwendung von antikörpern und analoga daraus
EP2427479A4 (de) Antikörper und verfahren zu ihrer verwendung
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
EP1933884A4 (de) Abbildungswirkstoffe und verfahren zu ihrer verwendung
EP1915177A4 (de) Alpha-synuclein-antikörper und relevante verfahren
EP2019679A4 (de) Glucosetransporthemmer und anwendungsverfahren
EP2242768A4 (de) Kreuzneutralisierung menschlicher monoklonaler antikörper gegen sars-cov und verfahren zu deren anwendung
EP1940466A4 (de) Monoklonaler antikörper gegen addl und anwendung davon
EP2285462A4 (de) Chromatographiesysteme und sie verwendende verfahren
EP2046413A4 (de) Medizinische systeme und anwendungsverfahren
EP2236604A4 (de) Anti-nr10-antikörper und verwendung davon
EP2038252A4 (de) Substituierte acylanilide und verfahren zu ihrer verwendung
EP2054049A4 (de) Substituierte acylanilide und verfahren zu ihrer verwendung
EP1949105A4 (de) Mit diabetes assoziierte marker und verfahren zur verwendung davon
PT2059535E (pt) Anticorpos específicos do prlr e suas utulizações
EP2171460A4 (de) Materialien zur erfassung von polynukleotiden und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090303

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100624

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20100618BHEP

Ipc: C07K 16/24 20060101AFI20100618BHEP

17Q First examination report despatched

Effective date: 20110329

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150714